Bullish Analyst Opinion on Dyne (DYNE) Follows Rare Disease Drug Progress in Japan

Dyne Therapeutics Inc. (NASDAQ:DYN) is one of the 13 hot stocks to buy with the highest upside potential. As of February 13, nearly 90% of analysts who cover the stock have assigned a Buy or equivalent rating. The consensus 1-year median price target of $39.5 implies a 138% upside.

Earlier, on January 21, Francois Brisebois from LifeSci Capital reiterated a Buy rating on Dyne Therapeutics Inc. (NASDAQ:DYN), with a price target of $44.

Meanwhile, on January 20, Dyne Therapeutics Inc. (NASDAQ:DYN) announced that the Ministry of Health, Labour and Welfare in Japan granted Orphan Drug designation to zeleciment basivarsen (z-basivarsen) for the treatment of myotonic muscular dystrophy type 1 (DM1). In Japan, the Orphan Drug designation is granted to drugs intended for the treatment of rare diseases affecting fewer than 50,000 patients in the country and for which there is a high medical need. Benefits include subsidies for development costs and potential market exclusivity for up to 10 years, if approved. Z-basivarsen has also been granted Breakthrough Therapy, Fast Track, and Orphan Drug designations from the U.S. Food and Drug Administration (FDA), as well as an Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of individuals with DM1.

Dyne Therapeutics Inc. (NASDAQ:DYN) develops innovative, life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy.

While we acknowledge the potential of DYN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Stocks Under $3 to Buy Right Now and  10 Best High-Upside Materials Stocks to Buy

Disclosure: None. This article is originally published at Insider Monkey.